Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Sara Lonardi, Fotios Loupakis et al.|The Lancet Oncology|2020Cited by 322
Comparative Analysis of Fecal Microbiota in Healthy Controls and Pancreatic Cancer Patients: A Focus on Tumor Localization Differences in Pancreatic Head and Body–TailAnnacandida Villani, Valerio Pazienza, Gandino Mencarelli et al.|Cancer Medicine|2025Cited by 0